HIV infection and its association with an excess risk of clinical fractures: A nationwide case-control study

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 1, 2014, Pages 90-95

  Prieto Alhambra, Daniel ^a,b,c,d   Güerri Fernández, Robert ^c,e   De Vries, Frank ^b,f,g,h   Lalmohamed, Arief ^h,i   Bazelier, Marloes ^h   Starup Linde, Jakob ^j   Diez Perez, Adolfo ^c,e   Cooper, Cyrus ^a,b   Vestergaard, Peter ^j  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Department of Internal Medicine and Infectious Diseases Parc Salut Mar ^*  (Spain)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UTRECHT UNIVERSITY   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j AALBORG UNIVERSITY   (Denmark)

more..

Author keywords

bone; electronic health records; epidemiology; fratures; HIV; osteoporosis

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; HYPNOTIC SEDATIVE AGENT;

ADULT; ALCOHOLISM; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG USE; EMPLOYMENT STATUS; FEMALE; FOREARM FRACTURE; FRACTURE; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MAJOR CLINICAL STUDY; MALE; MARRIAGE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; FRACTURES, BONE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RISK ASSESSMENT; YOUNG ADULT;

EID: 84898543288     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000112     Document Type: Article

References (29)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20: 2165-2174.
2. Mills EJ, Barnighausen T, Negin J. HIV and aging - preparing for the challenges ahead. N Engl J Med. 2012;366:1270-1273.
3. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-808.
4. Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21:617-623.
5. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287:2398-2399.
6. Andersen TF, Madsen M, Jorgensen J, et al. The Danish national hospital register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
7. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
8. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1-10.
9. Wacholder S, McLaughlin JK, Silverman DT, et al. Selection of controls in case-control studies. I. Principles. Am J Epidemiol. 1992;135: 1019-1028.
10. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
11. Bonjoch A, Figueras M, Estany C, et al Osteoporosis Study Group. High prevalence of and progression to low bone mineral density in HIVinfected patients: a longitudinal cohort study. AIDS. 2010;24:2827-2833.
12. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93: 3499-3504.
13. Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: a longitudinal study. J Clin Endocrinol Metab. 2012;97:554-562.
14. Guerri-Fernandez R, Vestergaard P, Carbonell C, et al. "HIV infection is strongly associated with hip fracture risk, independently of age, gender and co-morbidities: a population-based cohort study." J Bone Miner Res. 2013;28:1259-1263.
15. Young B, Dao CN, Buchacz K, et al HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52:1061-1068.
16. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and highenergy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285-293.
17. Collin F, Duval X, Le Moing V, et al; ANRS CO8 APROCOCOPILOTE study group. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009;23: 1021-1024.
18. Womack JA, Goulet JL, Gibert C, et al Veterans Aging Cohort Study Project Team. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6:e17217.
19. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42: 1014-1020.
20. Grund B, Peng G, Gibert CL, et al INSIGHT SMART Body Composition Substudy Group. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519-1529.
21. Womack JA, Goulet JL, Gibert C, et al Veterans Aging Cohort Study Project Team. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis. 2013;56:1498-1504.
22. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis. 2012;205(suppl 3):S391-S398.
23. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825-831.
24. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
25. Gallant JE, Staszewski S, Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
26. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481-1488.
27. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford). 2008;47:1635-1640.
28. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145:3297-3303.
29. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol. 2007;79:1446-1454.